Clinical trials: Respiratory Infectious Diseases
Influenza Virus Infection, Trained Immunity
Effects of BCG on Influenza Induced Immune Response
In the present study, the investigators want to investigate whether prior BCG-vaccination improves the efficacy of influenza ("the flu") vaccination in young and/or old healthy volunteers and consequently could protect against…
- Trial name
- NCT02114255
- Testing
- BCG
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Acute Lower Respiratory Tract Infection, Pneumonia
Fast Identification of Pathogen in the Setting of Pneumonia Using Multiplex PCR
With this study the investigators want to determine, if a fast identification of germs, causing infections of the lower respiratory tract, is possible through the use of Multiplex PCR technology - a method that allows on time…
- Trial name
- NCT01858974
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Göttingen
Covid19, type1diabetes
Covid-19 Infection and New Onset Type 1 Diabetes
Although recognized as an autoimmune disease the etiology of type 1 diabetes remains unknown. Virus infections has been suggested as a possible agent triggering the autoimmune reaction finally resulting in beta-cell destruction…
- Trial name
- NCT04623697
- Where
- Denmark
- Volunteers
- 600 people
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Hepatitis B, Polio
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule
To demonstrate that the immune response to hepatitis B antigen of the DTaP-IPV-Hep B-PRP~T is non-inferior to that of the association of PENTAXIM™ and ENGERIX B® one month after a three dose (2-3-4 month) primary series.
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00315055
- Testing
- DTaP-IPV-HB-PRP~T vaccine, DTaP-IPV//PRP~T combined, Hepatitis B vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Covid-19
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.
- Trial name
- NCT04522817
- Testing
- CLBS119
- Where
- United States
- Sponsor
- Lisata Therapeutics, Inc.
SARS-CoV-2 Infection
Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19
A Phase II/III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2
- Trial name
- NCT05633433
- Testing
- Azvudine
- Where
- 10 sites in Malaysia, Philippines
- Volunteers
- 1,550 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Pneumonia, Ventilator-Associated
Biomarkers for Ventilator-associated Pneumonia
The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.
- Trial name
- VAPmarkers (NCT05117125)
- Testing
- Heparin-binding protein, Interleukin-26, Microbiome
- Where
- 5 sites in Norway, Portugal and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Region Skane
Airway Obstruction, Respiratory Infection
Impact of High Flow Therapy on Complications Related to Airway Stenting
The application of HFNC therapy in patients with airway stent, improving both humidification and clearance of the airway secretion, could potentially reduce the risk of mucoid impaction, respiratory infections and granulation.
- Conditions
- Airway Obstruction, Respiratory Infection, Mucus; Plug
- Trial name
- HiSTENT (NCT06069817)
- Testing
- High flow nasal cannula, nebulized normal saline
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Cardarelli Hospital
Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease
Understanding Pneumococcal Carriage and Disease 2017-2020
Streptococcus pneumoniae is a type of bacteria that is carried (lives) in the nose of most individuals and can sometimes go on to cause severe infections such as meningitis and pneumonia.
- Conditions
- Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease, Streptococcal Pneumonia
- Trial name
- NCT03102840
- Testing
- Nasopharyngeal swab, blood sampling
- Where
- United Kingdom
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Schistosomiasis
Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis
The primary objective of this clinical investigation is to determine the percentage of travelers and migrants diagnosed with chronic schistosomiasis according to site-specific diagnostic practice who have active infection at the…
- Trial name
- SchistAct (NCT06873308)
- Testing
- UCP-LF CAA assay
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 278 people
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Upper Respiratory Tract Infection
Probiotic S. Salivarius K12 for the Prevention of Upper Respiratory Tract Infection in Nursery-age Children
The purpose of this retrospective study is to assess the treatment benefits of probiotic Streptococcus salivarius K12 for the prevention of recurrent bacterial and viral infections of the pharynx, tonsils and ears in children…
- Trial name
- PUNK (NCT05840926)
- Testing
- Probiotic Streptococcus salivarius K12, No probiotic supplementation
- Where
- Pakistan
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- Liaquat University of Medical & Health Sciences
COVID-19, SARS-CoV 2
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
- Trial name
- NCT04372017
- Testing
- Hydroxychloroquine, Vitamin D
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sanford Health
SARS-Cov-2 Infection, Rheumatoid Arthritis
Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthritis Patients
Immune aging or immunosenescence is characterized by a loss of T cell clonal diversity and a contraction of naïve T cells with proliferative capacity associated with the functional impairment of many others immune cells as well…
- Trial name
- SENO-COVID (NCT04880720)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
URTI - Viral Upper Respiratory Tract Infection, Prevention
Clinical Trial to Evaluate the Efficacy of a Probiotic Preparation in the Prevention of Upper Respiratory Tract Infections in Adults
Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper…
- Trial name
- NCT07091955
- Testing
- Lacticaseibacillus rhamnosus CRL1505
- Where
- Spain
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bioithas SL
COVID-19
Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)
There is currently no effective treatment for COVID-19 except best supportive care. The aim is assess the safety, tolerability and efficacy of convalescent plasma for treatment of patients with varying degrees of COVID-19 illness.
- Trial name
- NCT04390178
- Testing
- SARS-CoV-2 convalescent plasma
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Joakim Dillner
COVID-19, Infection Viral
A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
An open label, dose escalation, and dose expansion study to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2).
- Conditions
- COVID-19, Infection Viral, Infections
- Trial name
- NCT05069623
- Testing
- VB10.2129, VB10.2210
- Where
- 2 sites in Norway
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Nykode Therapeutics ASA
SARS-CoV Infection
COVID-19 Persistence in Stool
This is a longitudinal study in which participants that have been confirmed by a National Health Service (NHS) swab test as COVID-19 positive will be asked to provide faecal and saliva samples, and complete short health/lifestyle…
- Trial name
- CoPS (NCT04546776)
- Where
- 3 sites in United Kingdom
- Volunteers
- 105 people
- Sponsor
- Quadram Institute Bioscience
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia
Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
The purpose of this study is to compare the clinical cure rates of two dosing regimens of iclaprim with vancomycin (every 12 hours [q12h]) in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated…
- Conditions
- Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia, Health-Care-Associated Pneumonia
- Trial name
- NCT00543608
- Testing
- iclaprim, vancomycin
- Volunteers
- 135 people
- Sponsor
- Arpida AG
COVID-19, Diabete Mellitus
Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients…
- Trial name
- NCT05867017
- Testing
- Measure of physiologic parameters
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Health Science Center at San Antonio